TRICAPITAL portfolio company Syntropharma specializes in transdermal delivery of medicines, and their novel Naltrexone transdermal patch (Nalsyn) has recently been granted a patent in the USA. The product will now commence a Phase I study, before entering full development. Nalsyn is being positioned for the treatment of patients suffering with alcohol and opiate addiction problems.
TRICAPITAL chairman Jamie Andrew welcomed the news: “This is a significant step on Syntropharma’s journey, and helps to strengthen their position among the new generation of pharmaceutical companies creating innovative transdermal products”.
Syntropharma is based in the Scottish Borders, and its development activities are focused on the repositioning and reformulation of existing approved drugs. The adoption of this strategy has helped Syntropharma to develop a number of transdermal products quickly and efficiently.
To find out more about TRICAPITAL and investing in Syntropharma, contact us here.
Visit the Syntropharma website.